On February 16, 2023 Tyligand Bioscience, a clinical stage biotech company focused on the development of innovative drugs to treat drug-resistant tumors, reported that it has received Investigational New Drug clinical trial approval recently from both U.S. Federal Food and Drug Administration (FDA) and Chinese National Medical Product Administration (NMPA) for TSN222, the world’s first dual action small molecule immune agonist (Press release, Tyligand Bioscience, FEB 16, 2023, View Source [SID1234644988]). TSN222 is a novel bifunctional small molecule designed with sequential and synergistic release of both immune agonism and cytotoxic functions modulated in vivo by pharmacokinetics. It not only activates interferon production in the tumor microenvironment, but also selectively kills tumors cells to prime the adaptive immune system. TSN222’s preclinical data showed good tolerability, excellent tumor suppression efficacy and sustainable immune memory.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"TSN222 is the first product off the DATIA (Dual Action Tumor Immune Agonist) platform to enter clinical development," said Tony Zhang, PhD., co-founder and CEO of Tyligand, " The achievement of this important milestone demonstrates the team’s ability to produce quality clinical candidates by actualizing the "Tie + Ligand" platform concept with innovative molecular design capabilities. We will build a differentiated product pipeline based on the DATIA platform and actively expand external collaborations to accelerate the discovery and development of more effective and accessible therapeutic options for the patients."